A Patent Trial and Appeal Board panel agreed with Mylan that one of Biogen's patents on Tecfidera is void, clearing the way for generic versions of the multiple sclerosis drug as soon as 2021.
Patent court opens door to generic versions of blockbuster MS drug
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.